COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection. Comprehensive Datasets

Loading...
Thumbnail Image

Persistent link to this item

Statistics
View Statistics

Collection period

2020-12-30
2022-11-27

Date completed

Date updated

Time period coverage

Geographic coverage

Source information

Journal Title

Journal ISSN

Volume Title

Title

COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection. Comprehensive Datasets

Published Date

2025-02-03

Group

Author Contact

Bramante, Carolyn
covidout@umn.edu

Type

Dataset
Human Subjects Data

Abstract

The COVID-OUT clinical trial was a decentralized, randomized, placebo controlled clinical trial of early outpatient treatment of SARS-CoV-2 infection. The trial used a 2x3 factorial design to test metformin versus placebo, ivermectin versus placebo, and fluvoxamine versus placebo.

Description

This is the data for the COVID-OUT clinical trial. 1) "covid_out_data_2023-06-27.csv" - This database includes all the data needed to replicate the analyses in the acute outcomes paper (PMC9945922) and the long-term outcomes paper (PMC11259948). The code used for analyzing the data in the papers is in the data dictionary file. 2) "covid_out_viral_load_data.csv" - This database includes all the data needed to replicate the analyses in the viral load outcomes paper (PMC11327787). The code used for analyzing the data in the papers is in the data dictionary file.

Referenced by

1) Acute outcomes paper: https://www.nejm.org/doi/full/10.1056/NEJMoa2201662
2) Long term outcomes paper: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00299-2/fulltext
3) Viral Load Outcomes paper: https://academic.oup.com/cid/article/79/2/354/7660393

Related to

Replaces

item.page.isreplacedby

Publisher

Funding information

Supported by the Parsemus Foundation, Rainwater Charitable Foundation, Fast Grants, and UnitedHealth Group Foundation.
The fluvoxamine placebo tablets were donated by Apotex Pharmaceuticals.
The ivermectin placebo and active tablets were donated by Edenbridge Pharmaceuticals.
Dr. Bramante was supported by grants (KL2TR002492 and UL1TR002494) from the National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health (NIH) and by a grant (K23 DK124654–01-A1) from the National Institute of Diabetes and Digestive and Kidney Diseases of the NIH.
Dr. Buse was supported by a grant (UL1TR002489) from NCATS.
Dr. Nicklas was supported by a grant (K23HL133604) from the National Heart, Lung, and Blood Institute of the NIH.
Dr. Odde was supported by the Institute for Engineering in Medicine, the Medtronic Professorship for Engineering in Medicine, and by grants (U54 CA210190 and P01 CA254849) from the National Cancer Institute of the NIH.

item.page.sponsorshipfunderid

item.page.sponsorshipfundingagency

item.page.sponsorshipgrant

Previously Published Citation

Other identifiers

Suggested citation

Bramante, Carolyn. (2025). COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection. Comprehensive Datasets. Retrieved from the Data Repository for the University of Minnesota (DRUM), https://hdl.handle.net/11299/269790.

Content distributed via the University Digital Conservancy may be subject to additional license and use restrictions applied by the depositor. By using these files, users agree to the Terms of Use. Materials in the UDC may contain content that is disturbing and/or harmful. For more information, please see our statement on harmful content in digital repositories.